Day 1 - Tuesday, 3 May 2016
Meeting category
Date(s)
3 May 2016 - 6 May 2016
Location
Yaoundé,
Cameroon
INTEREST 2016
Related Enduring Materials
Enduring Materials
Symposium: AbbVie - The Road to 2030 -
90-90-90: Closing the Gaps
Sylvia Ojoo, MBChB
University of Maryland Kenya, Kenya
Evolving Treatment Paradigms: Relevance in Resource- Limited Settings
Session: Advances in Laboratory Science and Implementation -
Progress on viral load monitoring, laboratory quality assurance, point of care
Session: Emerging Pathogens in West-Africa: Lessons From and For HIV -
Chairs
Catherine Hankins, MD, PhD, FRCPC, CM
Netherlands/Canada
Peter Kilmarx
USA
Lessons learnt from Ebola Vaccine Trials in Emergency Settings
Lessons learnt from Ebola Therapeutic Trials and Survivor Cohort Studies
Lessons learnt About Good Participatory Practices in Prevention and Treatment Trials for HIV and for Emerging Pathogens
Lessons learnt About the Ethics of Trial Conduct in Emergency Settings
Ebola to Lassa Fever: Leassons learnt
Session: Official Opening Session -
Welcome address by the Yaoundé City Council Government Delegate
Gilbert Tsmini Evouna
Mayor, Cameroon
Opening speech by the Minister of Health, Cameroon
HIV in Cameroon
Progress in HIV Prevention and Treatment Scale-Up in Sub-Saharan Africa
The Joep Lange Institute / Art and Science in the HIV response
Alexander Kohnstamm
The Joep Lange Institute, the Netherlands
Day 2 -Wednesday, 4 May 2016
Session: Addressing 90-90-90 Implementation Challenges on the Road to 2020 and 2030 -
HIV Testing Strategies: How to Reach 90% Knowledge of Serostatus (including the role of self-testing)
Immediate Offer of HIV Treatment: How To Deliver on the Second 90 (including Supply Chain Management and Drug Stockouts)
Insights and Lessons Learned on Retention, Adherence, and Achieving and Maintaining Viral Suppression: The Third 90
Symposium: Janssen Therapeutics - Continuum of Care for Children and Adolescents -
Knowing Your Data - Update on the Epidemiology of HIV in Children and Adolescents
Being Proactive - HIV Prevention in Adolescents
90-90-90 for all - Scale up of HIV Treatment for Adolescents
Supporting Beyond Treatment - Care for HIV Positive Adolescents
Oral Abstract Presentations -
Decline in positivity rates among HIV-exposed infants with changes in PMTCT ARV regimens in Nigeria: evidence from 7 years of field implementation
Favourable outcomes of paediatric second-line protease inhibitor-based antiretroviral treatment in Uganda
Transmitted Drug Resistance and First-line ART Treatment Outcomes in Ugandan Children
H. Mugerwa
Uganda
Ultra-deep pyrosequencing of paediatric HIV-1 drug resistance and coreceptor suggests possible suitability of protease inhibitors and maraviroc at younger ages in Cameroon
Formal Debate: Resolved that 90-90-90 Cannot be Attained -
Affirming the motion
Opposing the motion
Kenly Sikwese
African Community Advisory Board
Oral Abstract Presentations -
Prevalence of non-infectious co-morbidities among HIV-positive subjects stably treated with tenofovir, lamivudine and ritonavir-boosted lopinavir in Cameroon
Current profile of dermatological diseases and events during HIV in Dakar
Quality of life among HIV/AIDS patients on anti retro-viral therapy at Letlhakane primary hospital (Botswana): a cross sectional study
Maximizing EID opportunities using the DBS Mentor Approach in Rural HIV Clinics in South-Eastern Nigeria
Model-based pediatric dosing of ritonavir-boosted Darunavir: an alternative to WHO guidelines
Getting pregnant in antiretroviral clinical trials: women choice and safety needs. Experience from the ANRS12169-2LADY and ANRS12286- MOBIDIP trials
Retention in care among HIV-infected pregnant mothers on lifelong antiretroviral therapy (art) in Uganda
Immunologic Criteria are Poor Predictors of Virologic Outcomes: Implications for HIV Monitoring in a Large Treatment Program in Nigeria
Factors associated with virologic failure in HIV infected individuals in Mansa district, Zambia
Day 3 - Thursday, 5 May 2016
Session: HIV prevention in 2016 -
Sustaining progress on scale-up of voluntary medical male circumcision (VMMC), including role of devices and early infant male circumcision
Trial, post-trial, & demonstration project results for Pre-exposure Prophylaxis (PrEP)
New evidence on oral and topical PrEP for women: rings, gels, injectables
Debate: Gilead: The Continent of Africa is Ready for HIV Pre-Exposure Prophylaxis (PreP) Implementation -
PreP
Speaker for the Proposition
Speaker for the Opposition
Rebuttal Speaker 1
Rebuttal Speaker 2
Community Advocate
Oral Abstract Presentations -
Predictors of HIV-testing in South African adolescents: schools-based testing, pregnancy and sexual experience
EDCTP as a model for Europe-Africa partnership on HIV/AIDS research and capacity development: Examples from Cameroon
Accumulation of HIV-1 drug resistance after continued virological failure on first-line antiretroviral therapy in adults and children
Tenofovir-containing first-line ART favourably reduce inflammation markers compared to thymidine analogue nucleoside reverse-transcriptase inhibitors
Session: Progress and challenges in reaching key populations -
Sex work in sub-Saharan Africa
=
Drug Use in sub-Saharan Africa: opportunities and challenges
Men who have sex with men in sub-Saharan Africa
Panel discussion: Challenges in engaging key populations in HIV prevention in sub-Saharan Africa
Oral Abstract Presentations -
Finding the first 90% to achieve epidemic control
Operational research studies among MSM in Cameroon: Linkage to treatment challenges
Pre-Clinical Evaluation of optimized Immunogens targeting the neutralizing epitopes in MPER of HIV envelope Glycoprotein
Identification of Rare HIV-1 Group N and HTLV-3 Strains in Rural South Cameroon
HIV-1 group O infection in Cameroon from 2006 to 2013: prevalence, genetic diversity, evolution and public health challenges
The effect of antiretroviral naïve HIV-1 infection on the ability of autologous NK cells to produce IFNg unpon exposure to Plasmodium falciparum- infected Erythrocytes
Evaluating plasmatic biomarkers as disease signatures for the point of care monitoring of HIV-1 and comorbidities in resource limited regions.
Immune reconstitution and skewed responses after ART initiation in HIV I infected Ugandans
Outcomes of second-line therapy in HIV positive adults attending for routine care at Yaoundé Central Hospital
Day 4 - Friday, 6 May 2016
Session: Global Health Strategies and Financing -
Global Health in the Era of Ebola and Zika
Kevin de Cock
Centers for Disease Control and Prevention, Kenya/USA
HIV Leadership and Financing Strategies for Countries in sub-Saharan Africa
Session: Sponsor symposium: Roche -
Roche Global Access Program (GAP) in support of UNAIDS 90/90/90
Souleymane Soumare
TBS, Senegal
Souleymane Sawadogo
CDC Atlanta, USA
Overview
Welcome
We are pleased to look back on a very successful 10th International Workshop on HIV Treatment, Pathogenesis, and Prevention Research in Resource-Limited Settings, held in Yaoundé, Cameroon this year.
More than 500 participants registered for this important event, also known as the "African CROI".
The Organizing Committee and the Organizing Secretariat would like to thank the invited speakers and all participants for their contribution to this meeting! In particular we would like to thank our workshop sponsors: Abbvie, Gilead Sciences, Janssen Pharmaceutica NV, GSK/ViiV Healthcare, Roche, and Mylan. Without their financial contribution this workshop would not have been made possible. We would also like to thank our supporters: UNAIDS, ANRS, AMC Medisch Centrum, Botswana HIV Clinicians Society, Erasmus MC University Medical Centre, IAPAC, Namibian HIV Clinicians Society, PharmAccess, RESAPSI, and Southern African HIV Clinicians Society.
Support
Platinum level
Gold Level
Silver level
Support
Endorsers
Language
Related Programs
